What is the role of baricitinib in the treatment of COVID-19?

Updated: Jan 12, 2021
  • Author: Setu K Patolia, MD, MPH; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print


Baricitinib is a selective inhibitor Janus kinase 1 and 2. It is given orally. It inhibits the intracellular signalling pathway of cytokines such as IL-2, IL-6, IL-10, interferon-γ, and granulocyte macrophage colony-stimulating factor. It has been also shown to improve the lymphocyte count and prevent entry of the virus into the cell. In the Adaptive COVID-19 Treatment Trial-2 (ACTT-2), patients were randomized to receive either baricitinib or placebo. [54] Both groups received remdesivir. This randomized controlled trial showed that the combination of baricitinib and remdesivir was associated with a reduction in the time to recover, as well as acceleration in improvement in clinical status as compared with the combination of remdesivir and placebo. It was approved by the FDA as a medication to be used under an Emergency Use Authorization (EUA).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!